VPS9D1-AS1 gene rs7206570 polymorphism associated with the clinical stage of colorectal cancer and binding with hsa-miR-361-3p

Human Cell ◽  
2022 ◽  
Author(s):  
Xueren Gao ◽  
Shulong Zhang ◽  
Xiaoting Wang
Keyword(s):  
Colorectal Cancer ◽  
Clinical Stage

Abstract 2266: Characterization of activins and their related molecules in colorectal cancer according to clinical stage, tumor sidedness and the expression of PI3K/mTOR proteins

2021 ◽  
Author(s):  
Mohammed A. Baghdadi ◽  
Jawwad Ahmad ◽  
Shakir Idris ◽  
Jamal Zekri ◽  
Abdelrazak Meliti ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Stage

Minimal residual disease by circulating tumor DNA analysis for colorectal cancer patients receiving radical surgery: An initial report from CIRCULATE-Japan.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 3608-3608
Author(s):  
Hiroki Yukami ◽  
Yoshiaki Nakamura ◽  
Jun Watanabe ◽  
Masahito Kotaka ◽  
Kentaro Yamazaki ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dna Analysis ◽  
Residual Disease ◽  
Clinical Stage ◽  
Circulating Tumor Dna ◽  
Patient Specific ◽  
Detection Rates ◽  
Initial Report ◽  
Post Surgery ◽  
Tumor Dna

3608 Background: Circulating tumor DNA (ctDNA) analysis can be used to predict the risk of recurrence by detecting molecular residual disease (MRD) in patients with colorectal cancer (CRC). We are conducting a prospective observational study to monitor MRD status in patients with clinical stage II–IV or relapsed CRC amenable to radical surgical resection (GALAXY study), as part of the CIRCULATE-Japan, a nationwide ctDNA-guided precision adjuvant therapy project. Methods: Analysis of ctDNA is being performed at pre- and post-surgery timepoints and will continue periodically for up to 2 years using Signatera, a personalized, tumor-informed ctDNA assay that is designed to track 16 patient-specific somatic variants based on whole-exome sequencing of tumor tissue. The association of peri-operative ctDNA status with clinicopathological characteristics was investigated. Results: As of January 13, 2021, 941 patients have been enrolled in the GALAXY study, of which 400 patients had their pre-operative ctDNA status evaluated. Of the 400 patients, baseline ctDNA was detected in 92% (367/400) of the patients: consisting of 35 patients with pathological stage (pStage) I, 135 with pStage II, 152 with pStage III, and 78 with pStage IV or relapsed disease (pStage IV/R). Patient-specific Signatera assays targeting 16 variants were designed for 100% of the patients. Out of the 6400 designed variants 99.3% passed quality control in the plasma analysis and produced the final results. Among 4425 genes selected for 400 patients, 3330 genes were selected for only one patient, while TP53 was the most commonly selected in 113 patients (28%). Median ctDNA levels, measured in mean tumor molecules per mL of plasma and ctDNA detection rate, stratified by stage are presented in table. Positive ctDNA status post-surgery was significantly associated with advanced pStage, pT and pN, and lymphovascular invasion. Of the 13 patients with recurrence, 10 were detected with a positive ctDNA at 4-weeks post-surgery, before confirmation of recurrence by the radiological imaging. Conclusions: Preoperative ctDNA detection rates were observed to be in >90% in patients with pStage II–III by personalized ctDNA assay based on unique somatic variants, specific to each patient. ctDNA- based MRD detected post-surgery (4W) was significantly associated with certain known clinicopathological factors for recurrence with ctDNA positivity associated with a very short-term of recurrence. Clinical trial information: 000039205. [Table: see text]

scholarly journals YAP Levels Combined with Plasma CEA Levels Are Prognostic Biomarkers for Early-Clinical-Stage Patients of Colorectal Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Zihui Xu ◽  
Hui Wang ◽  
Ling Gao ◽  
Hongfeng Zhang ◽  
Xiangyang Wang
Keyword(s):  
Colorectal Cancer ◽  
Lymphatic Metastasis ◽  
Early Stage ◽  
Clinical Stage ◽  
Survival Rates ◽  
Immunohistochemical Analysis ◽  
High Plasma ◽  
Node Ratio ◽  
Early Clinical Stage ◽  
Cancer Tissues

Background. Colorectal cancer (CRC) is one of the most common cancers worldwide. Surgical operation is routinely applied to patients with CRC. An important part of postoperative care for patients is to assess the prognosis of patients, especially those with early-stage cancers. However, effective biomarkers for CRC prognosis remain inadequate. The purpose of this study was to assess the prognostic potential of Yes-associated protein (YAP) and carcinoembryonic antigen (CEA) in early-stage CRC. Methods. A total of 116 matched pairs of CRC tissues and adjacent normal mucosae as well as 73 cases of metastatic lymph nodes were analyzed. Results. The results show that CRC tissues exhibited higher YAP expression compared with the adjacent normal mucosae. Immunohistochemical analysis shows that YAP expression in the CRC or lymphatic metastatic tissues was clearly higher than that in normal mucosae (P<0.01), whereas that in CRC tissues with lymphatic metastasis was higher than that in tissues without lymphatic metastasis (P<0.05). YAP expression is associated with serosal invasion, lymphatic metastasis, lymph node ratio, remote metastasis, Dukes stage, and CEA levels (P<0.05). YAP and CEA are independent predictors of the survival of CRC patients (P<0.05 and P<0.01). YAP predicted CRC prognosis primarily for patients with late-clinical-stage CRC (P=0.002), but not for patients with early-clinical-stage CRC (P=0.083). However, patients with high YAP and high CEA levels exhibited lower overall survival rates than those with low YAP expression in early-clinical-stage CRC (P<0.001). Conclusion. High YAP levels in the cancer tissues combined with high plasma CEA levels are potential biomarkers for predicting CRC prognosis in the early clinical stage.

Analysis of Tumor Volume Dynamics in Colorectal Cancer

2019 ◽  
Vol 7 (4) ◽  
pp. 81-87
Author(s):  
A. A. Filin ◽  
A. A. Sizov ◽  
E. E. Chupandina ◽  
V. I. Danilenko ◽  
D. Yu. Bugrimov ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Life Expectancy ◽  
Tumor Invasion ◽  
Tumor Volume ◽  
Clinical Stage ◽  
Age Groups ◽  
Tumor Localization ◽  
Regional Lymph Nodes ◽  
Degree Of Differentiation ◽  
Tumor Invasion Depth

The purposeof the study was to investigate the dynamics of tumor volume change in different age groups and its relation to the clinical (sex, age, stage of disease, life expectancy) and morphological parameters (tumor localization, metastases to regional lymph nodes, tumor invasion depth, histological type and degree of differentiation).Material and methods.The data of 527 patients (men and women, age from 24 to 86 years) suffering from colorectal cancer who underwent primary resection of the tumor. Clinical data and protocols of pathologist were analyzed: clinical stage of the disease, tumor localization, life expectancy, macroscopic, microscopic description, diagnosis. Based on the data obtained from the gross description, the tumor volume was calculated.Results. The maximum incidence of colorectal cancer was observed in patients in the age group from 70 to 79 years, more than 90% of all patients are over 50 years old. The volume of the tumor in colorectal cancer varied significantly, but the dynamics of the increase of the average volume with age was not observed. Opposite, the largest neoplasms were found in the youngest patients.Conclusion. Obtained data shows that changes in the tumor volume in colorectal cancer is nonlinear. Indicators of tumor volume in different age groups show similar dynamics: the most common tumors are mediumsized, but the small and very large tumors are much less common, which can explain the low rates of detection of tumors of this localization in the early stages.

General epidemiologic colorectal cancer profile in Oncologos del Occidente from Colombia, South America.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e14693-e14693
Author(s):  
Tomas Sanchez Villegas ◽  
Carlos Raul Villegas Mejia ◽  
Jose Arnoby Chacon Cardona
Keyword(s):  
Colorectal Cancer ◽  
Rectal Cancer ◽  
Colon Cancer ◽  
Clinical Stage ◽  
Surgical Margin ◽  
Partial Report ◽  
Cancer Center ◽  
Positive Surgical Margin ◽  
Final Report ◽  
Preoperative Treatment

e14693 Background: The Colorectal Cancer is one of the most common cancer in the US and the fourth cancer for the developing countries like in our area. Methods: This is a preliminary and partial report of a retrospective analysis from our cancer records in Oncologos del Occidente a Private Oncologic Cancer Center from Colombia. Results: 663 patients (50% of final report) from January 1997 to June 2012 with Colon Cancer 306(46%), Rectal Cancer 309(47%) y Anal Cancer (7%); 51% female; median age 60(range 16-92. sd:13.929); Urban Area 91%. Clinical stage I (7%), IIA (19%), IIB (3%), IIIA (5%), IIIB (13%) and IIIC (10%), IV (11%), Adenocarcinoma 81%, Mucinous (8%); Well differentiated (63%), Poorly differentiated (7%); pretreatment Carcino-embryonic antigen mean 32.778 ng/ml (range 0.18-550.0), Adverse prognostic factors were Obstruction (39%), Ulceration (31%), Lymph Vascular Invasion (10%), T4 Stage (5%), Perforation (4%), Positive Surgical Margin (2%) with two factors 21% and three factors 7%; Low rectal cancer was 90%, Non-Surgical treatment was Chemotherapy (CT) (37%), CT/Radiotherapy (RT) (35%), CT and RT (8%), RT (3%), None (16%); preoperative treatment 37%, First line CT was based on 5FU/LV (52%); 20% relapsed and the main recurrence pattern was Local-marginal (25%), Liver (17%), Pelvic peritoneal (3%), Carcinomatosis (8%) and Lung (23); Rescue treatment was CT (10%), Surgery+CT (1%), CT+RT (1%) and Surgery (1%); the main rescue CT was Folfox 2%, 5FU/LV (3%), Capecitabine (3%), Mixed 6%; Surgical Lymph nodes mean excised was 10.037 (0-38 SD.7.554) and positive nodes mean was 1.972(0-29 SD 3.503); Overall Survival at 5 years for Colon cancer is 63% and 53% to 10 years and Rectal cancer to 5 and 10 years is 45% and 36% respectively (p=0.001). Conclusions: These results reflect the colorectal cancer behavior in a specific area of Colombia and the importance of a multidisciplinary work.

scholarly journals Prognostic Relevance and Function of MSX2 in Colorectal Cancer

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Jiancheng Liu ◽  
Huaying An ◽  
Wei Yuan ◽  
Qiang Feng ◽  
Lianzhen Chen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Stage ◽  
Total Mortality ◽  
Test Analysis ◽  
Akt Phosphorylation ◽  
Protein Levels ◽  
Patients With Diabetes ◽  
Chi Squared ◽  
And Function

Colorectal cancer patients with diabetes had the high risks of total mortality. High expression of MSX2 is related to development of diabetes. There are few reports about the clinical implications and function of MSX2 in colorectal cancer (CRC). The purpose of this study is to investigate the relationship between the expression of MSX2 and clinical relevance and discover the possible mechanism of MSX2 in the development of CRC. Compared with adjacent tissues, the expression of MSX2 was higher in tumor tissues in both mRNA and protein levels (P<0.01). Kaplan-Meier survival analysis showed that high mRNA expression of MSX2 was associated with short survival time (P=0.013). Chi-squared test analysis indicated that MSX2 expression was related to tumor size (P=0.04), tumor locus (P=0.025), clinical stage (P<0.001), tumor invasion (P=0.003), lymphatic metastasis (P=0.01), and distant metastasis (P=0.033). In vitro experiments demonstrated that knockdown of MSX2 expression attenuated cell proliferation and invasion, promoted cell cycle arrest and apoptosis, and inactivated Akt phosphorylation. In conclusion, MSX2 played a crucial role in the progression of CRC and may be a potential novel prognostic factor and therapeutic target for CRC therapy. Our work may provide certain enlightenment for investigating the mechanism of MSX2 in the process of diabetes.

Tumor Karyotype Predicts Clinical Outcome in Colorectal Cancer Patients

2004 ◽  
Vol 22 (13) ◽  
pp. 2623-2634 ◽  
Author(s):  
Georgia Bardi ◽  
Claus Fenger ◽  
Bertil Johansson ◽  
Felix Mitelman ◽  
Sverre Heim
Keyword(s):  
Colorectal Cancer ◽  
Chromosome Aberrations ◽  
Structural Changes ◽  
Patient Survival ◽  
Independent Predictor ◽  
Clinical Stage ◽  
Univariate Analysis ◽  
Disease Free Survival ◽  
Tumor Grade ◽  
Chromosome 8

Purpose To investigate the prognostic value of the overall karyotypic features and specific chromosome aberrations in colorectal cancer (CRC). Patients and Methods Cytogenetic features of 150 primary CRCs investigated at the time of surgery were correlated with patient survival by univariate and multivariate analyses, using classical clinicopathologic parameters as covariates. Results In univariate analysis, in addition to tumor grade and clinical stage, structural aberrations as well as rearrangements of chromosomes 8 and 16 were significantly correlated with shorter overall survival. Karyotypic complexity, rearrangements of chromosomes 8 and 16, and loss of chromosome 4 were significantly correlated with shorter disease-free survival. In multivariate analysis, in addition to tumor grade, the type of chromosome aberrations (structural or numerical), ploidy, and loss of chromosome 18 came across as independent prognostic factors in the group of all patients. In the subset of patients with stage I and II carcinomas, none of the clinicopathologic variables could independently predict patient survival, whereas the presence of structural chromosomal aberrations was the only independent predictor of poor prognosis. In the subset of patients with stage III carcinomas, the presence of structural changes of chromosome 8 was a stronger independent predictor of prognosis than was tumor grade. Conclusion Cytogenetic tumor features are valuable predictors of prognosis in CRC patients. The tumor karyotype should therefore be taken into account in the clinical management of patients with this disease, especially for patients having cancers of the early or intermediate stages I, II, and III.

scholarly journals Experiencia Quirúrgica en el Manejo del Cáncer de Recto. Hospital de SOLCA, Guayaquil – Ecuador

2020 ◽  
Vol 12 (2) ◽  
pp. 92-97
Author(s):  
Carlos Humberto Malatay González ◽  
Juan Bernardo Pazmiño Palacios ◽  
Luis Andrés Idrovo Murillo ◽  
Jhónatan Miguel Siguencia Muñoz ◽  
Adriana Ximena Bravo Andrade
Keyword(s):  
Colorectal Cancer ◽  
Neoadjuvant Therapy ◽  
Clinical Stage ◽  
Cross Sectional Study ◽  
Histological Type ◽  
Stage Iii ◽  
Malignant Neoplasms ◽  
Advanced Clinical Stage ◽  
Cross Sectional ◽  
Common Histological Type

BACKGROUND: Colorectal cancer is the third most common among malignant neoplasms worldwide. Treatment choice depends on the location of the tumor, among other factors, and varies from local excision to abdominoperineal resection, adjuvant or neoadjuvant therapy can be needed, depending on clinical stage. The purpose of this study was to determine the most common histological type of rectal cancer, establish the most frequent clinical stage at diagnosis, the most common surgical technique and complications. METHODOLOGY: A cross-sectional study was carried out, with 160 patients treated in the digestive surgery service of Hospital SOLCA, Guayaquil – Ecuador, between January 2011 and December 2016, with colorectal cancer histologically diagnosed and treated surgically. RESULTS: Female sex was the most affected, with 65.7%, 63.1% of the patients were diagnosed at stage III, adenocarcinoma was the most common histological type (73.7%), the tumor was more frequently located at a low level, in 67.5% of the patients. Surgery was scheduled for 83.7% of the patients, derivative colostomy was the most common surgical procedure for treatment (48.8%), and the most common complications were those related to the ostomy, in 9.4% of the patients. Immediate mortality was 1.2% and late mortality was 8.1%. CONCLUSION: This study evidenced that colorectal cancer affected with more frequency to women, mainly to people over 60 years old. Most of the patients were diagnosed with advanced clinical stage (III) carcinoma, most frequently adenocarcinoma. Derivative colostomy was the procedure of choice for most of the patients, most of them needed neoadjuvant therapy too. The most common postsurgical complications were those related to ostomies.

scholarly journals SCG2 is a Prognostic Biomarker Associated With Immune Infiltration and Macrophage Polarization in Colorectal Cancer

2022 ◽  
Vol 9 ◽  
Author(s):  
Hao Wang ◽  
Jinwen Yin ◽  
Yuntian Hong ◽  
Anli Ren ◽  
Haizhou Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Immune Cells ◽  
Macrophage Polarization ◽  
Clinical Stage ◽  
Enrichment Analysis ◽  
Functional Enrichment ◽  
Secretory Proteins ◽  
Advanced Clinical Stage ◽  
Multiple Tumor ◽  
Immune Infiltration

Colorectal cancer (CRC) is the second most lethal malignancy around the world. Limited efficacy of immunotherapy creates an urgent need for development of novel treatment targets. Secretogranin II (SCG2) is a member of the chromogranin family of acidic secretory proteins, has a role in tumor microenvironment (TME) of lung adenocarcinoma and bladder cancer. Besides, SCG2 is a stroma-related gene in CRC, its potential function in regulating tumor immune infiltration of CRC needs to be fully elucidated. In this study, we used western blot, real-time PCR, immunofluorescence and public databases to evaluate SCG2 expression levels and distribution. Survival analysis and functional enrichment analysis were performed. We examined TME and tumor infiltrating immune cells using ESTIMATE and CIBERSORT algorithm. The results showed that SCG2 expression was significantly decreased in CRC tumor tissues, and differentially distributed between tumor and adjacent normal tissues. SCG2 was an independent prognostic predictor in CRC. High expression of SCG2 correlated with poor survival and advanced clinical stage in CRC patients. SCG2 might regulate multiple tumor- and immune-related pathways in CRC, influence tumor immunity by regulating infiltration of immune cells and macrophage polarization in CRC.

scholarly journals Comparison of non-schistosomal colorectal cancer and schistosomal colorectal cancer

2020 ◽  
Author(s):  
Weixia Wang ◽  
Kui Lu ◽  
Limei Wang ◽  
Hongyan Jing ◽  
Weiyu Pan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Clinical Stage ◽  
Clinicopathological Features ◽  
Proportional Hazard ◽  
Node Metastasis ◽  
Cox Proportional Hazard ◽  
Kaplan Meier ◽  
Cox Proportional Hazard Regression

Abstract Aim: The purpose of this study was to compare clinicopathological features of patients with non-schistosomal and schistosomal colorectal cancer to explore the effect of schistosomasis on CRC patients` clinical outcomes. Methods: 351 cases of CRC were retrospectively analyzed in this study. Survival curves were constructed by using the Kaplan-Meier method. Univariate and multivariate Cox proportional hazard regression models were performed to identify associations with outcome variables.Results: Patients with schistosomiasis (CRC-S) were significantly older (Table 3, P＜0.001) than patients without schistosomiasis (CRC-NS). However, there were no significant differences between CRC-S and CRC-NS patients in other clinicopathological features. Schistosomiasis were associated with adverse overall survival upon K-M analysis (P=0.0277). By univariate and multivariate analysis, as shown in Table 2, gender (P=0.003), TNM stage (P＜0.001), schistosomiasis (P=0.025), lymphovascular invasion (P=0.030) and cancer node (P＜0.001) were all independent predictors in the whole cohort. When patients were stratified according to clinical stage and lymph node metastasis state. Schistosomiasis was also an independent predictors in patients with stage Ⅲ-Ⅳ tumors and in patients with lymph node metastasis, but not in patients with stage Ⅰ-Ⅱ tumors and in patients without lymph node metastasis.Conclusion: Schistosomiasis was significantly correlated with OS and it was an independent prognostic factor for OS in the whole cohort. When patients were stratified according to clinical stage and lymph node metastasis state, schistosomiasis was still an independent unfavorably prognosis factor for OS in patients with stage Ⅲ-Ⅳ tumors or patients with lymph node metastasis.

Sign in / Sign up

Export Citation Format

Share Document